• Platelet function may influence bleeding risk in thrombocytopenia, but useful tests are needed.
Summary. Background: Methods for testing platelet aggregation in thrombocytopenia are lacking. Objective: To establish a flow-cytometric test of in vitro platelet aggregation independently of the patient's platelet count, and examine the association of aggregation with a bleeding history in thrombocytopenic patients. Patients/methods: We established a flow-cytometric assay of platelet aggregation, and measured samples from healthy individuals preincubated with antiplatelet drugs, and samples from two patients with inherited platelet disorders. Then, we included 19 healthy individuals and 20 patients with platelet counts of ≤ 50 9 10 9 L -1 , diagnosed with acute myeloid leukemia or myelodysplastic syndrome. We measured platelet aggregation and platelet activation by platelet surface expression of activated glycoprotein IIb-IIIa, Pselectin and CD63 after addition of agonists: collagenrelated peptide, thrombin receptor-activating peptide (TRAP), and ADP. Results: The platelet aggregation assay showed a low intraserial coefficient of variation of ≤ 3%. Similar results were obtained for platelet-rich plasma and isolated platelets at platelet counts of > 10 9 10 9 L -1 ; otherwise, platelet isolation was required.
The platelet aggregation percentage decreased with increasing antiplatelet drug concentration. Platelet aggregation in patients was reduced as compared with healthy individuals: 42% (interquartile range [IQR] 27-58) versus 66% (IQR 60-67) for TRAP; 41% (IQR 25-48) versus 70% (IQR 69-72) for collagen-related peptide; and 44% (IQR 30-53) versus 65% (IQR 46-72) for ADP. Platelet activation after stimulation was reduced in patients and correlated with platelet aggregation (e.g. r = 0.78-0.81 when stimulated with collagen-related peptide). Platelet aggregation had a negative predictive value of 100% for a bleeding tendency among patients. Conclusion: The
Introduction
Platelets are pivotal in primary hemostasis, and bleeding risk is a concern in thrombocytopenic individuals [1] . Before the availability of platelet transfusions, bleeding was a contributory factor in 67% of deaths among patients with leukemia [2] . Unfortunately, clinically relevant bleeding still occurs on 17-25% of days in hospitalized cancer patients with platelet counts below 80 9 10 9 L -1 [3] . Despite having equally low platelet counts, not all patients with thrombocytopenia experience bleeding, and the reason for this remains unknown. Impaired platelet function may contribute to the increased bleeding risk in thrombocytopenic patients. However, the topic is poorly understood, because most platelet function tests have methodological limitations at low platelet counts [4] . For example, light transmission aggregometry (LTA), the gold standard for measuring platelet function, is recommended for platelet counts above 150 9 10 9 L -1 [5] . In contrast, flow cytometry is suited to investigate platelet function in thrombocytopenia, because it measures the characteristics of each platelet [4] . Recently, flow cytometry has been applied to quantify platelet aggregation based on principles adapted from assays of leukocyte aggregates [6] . Flow cytometry has been sparsely applied to study platelet function in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) [7] [8] [9] , and has never been used to measure platelet aggregation in these patients. We hypothesize that, independently of the patient platelet count, platelet aggregation in patients with AML or MDS is reduced as compared with healthy individuals. Furthermore, we hypothesize that, in patients with AML or MDS, a bleeding tendency is associated with reduced platelet aggregation.
In this article, we present a flow-cytometric platelet aggregation assay. The assay was applied to measure platelet aggregation in patients with AML and MDS, and we determined the association with the patients' bleeding tendency.
Materials and methods

Study design and participants
For the flow-cytometric platelet aggregation assay, we used blood from healthy blood donors aged ≥ 18 years. They were allowed to take over-the-counter drugs for up to 24 h before sampling. Plasma from one male AB RhD + donor was used as matrix in all flow-cytometric platelet aggregation experiments. Patients were aged ≥ 18 years, and diagnosed with AML or MDS in accordance with current guidelines [10] . Patients had a platelet count of ≤ 50 9 10 9 L -1 at the time of sampling.
Exclusion criteria were treatment within 14 days with drugs that affect platelet function or platelet transfusion within 7 days, or exposure to procedures or interventions, such as central venous catheter insertion or chemotherapy, on the day of sampling. Patients were questioned (by P.J.V.) about the occurrence of spontaneous bleeding within the month prior to study inclusion. Bleeding was graded by use of the bleeding assessment tool of the ISTH [11] ; clinically relevant bleeding corresponded to a score of ≥ 1, and was registered as absent or present. We also included two patients with known inherited platelet disorders and thrombocytopenia. The study was approved by the Regional Scientific Ethical Committees of Southern Denmark (s-20150161) and the Danish Data Protection Agency (2008-58-0035). Participants gave written informed consent, and the study was conducted in accordance with the guidelines of the 2013 Declaration of Helsinki.
Blood samples
Blood was drawn from a peripheral vein with a 21-gauge needle into BD Vacutainer tubes (Becton Dickinson, Franklin Lakes, NJ, USA) containing either 3.2% (0.109 M) trisodium citrate for platelet function measurements or EDTA for evaluation of hematology parameters on a Sysmex XN-9000 (Sysmex, Kobe, Japan).
Flow cytometry platelet aggregation assay
The final protocol Platelet-rich plasma was obtained by centrifugation of citrate-anticoagulated blood ( Fig. 1) for 10 min at 200 9 g, and transferred to Nunc Cryotubes (Thermo Fisher Scientific, Hvidovre, Denmark). To prevent platelet activation during the next centrifugation, we added acid-citrate-dextrose solution (10% v/v) and prostaglandin E 1 (Alprostadil 0.9 lmol L À1 ; Tocris, Bristol, UK). The sample was then centrifuged for 10 min at 1000 9 g, during which platelets were pelleted. The platelet pellet was washed and resuspended in dilution buffer (NaCl 134 mM, KCl 2.9 mM, MgCl 2 1 mM, glucose 5.6 mM, and HEPES 20 mM, pH 7.4). The resting state of platelets was confirmed by flow cytometry following P-selectin antibody labeling (eBioscience, San Diego, CA, USA). From isolated platelets, two fractions with platelet counts of 144 9 10 9 L -1 and 16 9 10 9 L -1 were made by adjustment with dilution buffer, and labeled with calcein acetoxymethyl ester (AM) ultrapure grade (CAMU) and calcein-AM Violet 450 (CV450), respectively (both from eBioscience). CAMU and CV450 stock was prepared according to the manufacturer's instructions, and diluted with phosphate-buffered saline (PBS) to working stock concentrations of 1 lM for CAMU and 21 lM for CV450. From each of these solutions, 5 lL was added per 100 lL of platelet suspension. Fractions were incubated in the dark for 15 min at 37°C. Donor plasma was prepared by double centrifugation of citrate-anticoagulated blood at 1000 9 g for 10 min, with disposal of the sediment after each centrifugation cycle, and stored at À 80°C.
For the platelet aggregation test, 70 lL of thawed donor plasma and 35 lL of each of the CV450-labeled or CAMU-labeled platelet fraction were mixed in 1.5-mL Safe-Lock tubes (Eppendorf, Hamburg, Germany) (hereafter designated the 'platelet mix'). Then, 3.5 lL of agonist was added, and either 2. Optimization of the protocol The effect of platelet count on platelet aggregation was investigated with serial dilutions of donor platelets while a fixed ratio between the two differently labeled platelet fractions was maintained. The optimum shaking time was found by transferring the platelet mix into fixation buffer at different time points. The effect of plasma was determined by systematically varying the fraction of plasma in the final mix. Dose-response curves for agonists were obtained. The intermediate precision was determined by analysis of separately prepared samples obtained from two individuals (six samples per individual). As supplements, we tested arachidonic acid (Sigma-Aldrich), ristocetin (Roche Diagnostics, Mannheim, Germany) and protease-activated receptor 4 (AYPGKF-NH₂; Bachem, Bubendorph, Schwitzerland) as agonists. We also evaluated the effect of replacing one platelet fraction in the mix with platelets from a healthy donor (n = 4). The effects on platelet aggregation of inhibitors in varying concentrations, i.e. abciximab 0.1-40 lg mL À1 and ticagrelor 0.006-20 lM, both from Selleckchem (Houston, TX, USA) or vorapaxar 3.13-500 nM (SCH530348; Axon Medchem, Groningen, the Netherlands), were evaluated. Samples were preincubated with the drug for 0.5 h (abxicimab) or 1 h (ticagrelor and vorapaxar) at 37°C. In all experiments, generic reagents were from Sigma-Aldrich. Sizing beads were Megamix from Biocytex (Marseille, France).
Flow-cytometric platelet aggregation in whole blood and platelet-rich plasma
After modifying the protocol, we applied it to donor samples of whole blood or platelet-rich plasma (n = 6). One undiluted fraction of the sample was labeled with CAMU, and another was diluted 1 : 10 v/v with dilution buffer and labeled with CV450. Seventy microliters of dilution buffer instead of donor plasma was added to the mix.
LTA
LTA with 96 wells was performed as previously described [12] . Platelet aggregation of calcein-AM-labeled versus unlabeled platelets was compared (n = 6 for each agonist).
Platelet reactivity and platelet surface receptor expression
For testing of platelet reactivity in vitro, 5-lL aliquots of whole blood were incubated for 10 min at room temperature in dilution buffer with 1 g L À1 bovine serum albumin and fluorophore-conjugated mAbs: phycoerythrin (PE)-conjugated glycoprotein (GP) Ib (CD42b, clone HIP1, dilution factor in final sample [DF] 78), allophycocyanin (APC)-conjugated P-selectin (CD62p, clone Psel.KO2.3, DF 325) (both eBioscience), PE-cyanine 7 (Cy7) granulophysin (CD63, clone H5C6, DF 13), and fluorescein isothiocyanate (FITC)-conjugated PAC-1 (DF 13) (both Becton Dickinson Bioscience, San Jose, CA, USA), which only binds to activated GPIIb-IIIa. In addition, either agonist or dilution buffer was added. The agonist was ADP 12.8 lM, TRAP 10 lM, or collagenrelated peptide 1.1 lg mL À1 , in a final sample volume of 65 lL. A negative sample was incubated with mAbs against CD63, CD42b, and PAC1, and with an anti-Pselectin matched APC-conjugated isotype control (eBioscience). EDTA (10 mM) was added to inhibit specific binding of PAC1 and CD63 mAbs [13, 14] . In a separate protocol, we evaluated the expression of platelet surface receptors as previously described [13] . Briefly, we used mAbs for PE-Cy7-conjugated GPIIb (CD41a, clone HIP8, DF 325), eFluor450-conjugated GPIX (CD42a, clone GR-P, DF 78), PE-conjugated GPIb, APC-conjugated GPIa (CD49b, clone P1H5, DF 39), and FITC-conjugated GPIIIa (CD61, clone VI-PL2, DF 130), or matching isotype controls, all from eBioscience. In both protocols, incubation was stopped by the addition of fixation buffer. Samples were acquired on the FACSCanto II and processed with KALUZA software 1.3 (Beckman Coulter, Brea, CA, USA). Platelets were gated on the basis of GPIb expression and scatter pattern. The results were expressed as mean fluorescence intensities (MFIs) or, in the platelet reactivity assay, as the percentage of platelets positive for P-selectin, CD63 and/or PAC1 as compared with the negative sample.
Statistics
Categorical variables are reported as frequencies and percentages. The distribution of data for continuous variables was evaluated with the Shapiro-Wilk test of normality and/or inspection of histograms. For continuous, normally distributed data, means and standard deviations (SDs) are reported; otherwise, medians and interquartile ranges (IQRs) are reported. For evaluation of protocol settings and effects of antiplatelet drugs, the paired Student's t-test was used. Group comparisons of non-normally distributed data were carried out with the Mann-Whitney U-test (unpaired results) or the Wilcoxon signed-rank test (paired results). Correlations were tested non-parametrically and reported as Spearman's rho. Missing values were omitted (two patients did not have platelet activation markers). Statistical procedures were performed with STATA 14.0 (StatCorp, College Station, TX, USA) and GRAPHPAD PRISM 5.0 (GraphPad Software, La Jolla, CA, USA). P-values were two-sided.
Results
The final protocol A representative plot of platelet aggregation is shown in Fig. 2 . CAMU/CV450 double-positive events were present in all stimulated platelet mixes. These events were, on average, larger (higher FSC) and more granular (higher side scatter) than single-positive events. Platelet surface expression of GPIb and P-selectin confirmed that all double-positive events consisted of activated platelets.
Megamix bead comparisons confirmed the size of singlepositive events to be within the size range of normal platelets. Thus, double-positive events were taken to represent platelet aggregates. Calcein-AM labeling did not reduce platelet aggregation as measured by LTA; collagen-related peptide-induced platelet aggregation was 83% for CAMU-labeled platelets and 79% for unlabeled platelets (P = 0.18, n = 6).
Optimization of the protocol
Flow-cytometric platelet aggregation declined at platelet counts of < 15 9 10 9 L -1 , and was significantly reduced at platelet counts of ≤ 5 9 10 9 L -1 (Fig. 3A) . Platelet aggregation results depended on the shaking time (Fig. 3B) , the plasma fraction (Fig. 3C) , and the agonist concentration ( Fig. 3D ) (n = 3). In the final protocol, we used a plasma fraction of 0.50, 5 min of shaking and a platelet count of 40 9 10 9 L -1 in the final mix (equivalent to 5.6 million platelets per test). This corresponded to approximately one blood tube (4.5 mL) per test at platelet counts of 5 9 10 9 L -1
. In the final assay, we used the lowest agonist concentration that resulted in maximal platelet aggregation. However, to ensure that the maximum aggregation for ADP was reached, we chose a higher agonist concentration because the variation in platelet aggregation results among healthy donors was higher than observed for the other agonists. The percentage coefficients of variations (CV%) for repeated preparations from blood drawn concomitantly from the same individual were 1% for TRAP, 2% for ADP, and 3% for collagen-related peptide. For platelet mixes, the mean relative change in platelet aggregation over a period of 90 min was 0-2%. The agonists arachidonic acid, ristocetin and AYPGKF-NH₂ were suitable for the assay, with aggregation responses of > 50%.
Mixing patient platelets (CAV450-labeled, one part) with donor platelets (CAMU-labeled, nine parts) yielded average absolute increases in aggregation of -7% to 12% for ADP, 10-20% for collagen-related peptide and 3-12% for TRAP as compared with platelet mix with patient platelets only.
The platelet aggregation assay is sensitive to the effects of antiplatelet drugs Abciximab and ticagrelor inhibited TRAP-induced and ADP-induced platelet aggregation. Abciximab also inhibited collagen-related peptide-induced platelet aggregation (Fig. 4) . At low abciximab concentrations, ADP-induced platelet aggregation appeared to be slightly increased with increasing abciximab concentration. Vorapaxar selectively inhibited TRAP-induced platelet aggregation. Platelet aggregate size decreased progressively with increasing antagonist concentrations (Fig. 4) .
Flow-cytometric platelet aggregation in patients with inherited platelet disorders
We included a male patient with genetically confirmed Wiscott-Aldrich syndrome, no bleeding tendency, and a platelet count of of 45 9 10 9 L -1 , and a female patient with suspected MYH-9-related thrombocytopathy (dominant inheritance of macrothrombocytopenia; D€ ohle leukocyte inclusions), no bleeding tendency, and a platelet count of 54 9 10 9 L -1
. Both showed normal flow-cytometric platelet aggregation as compared with healthy individuals (data not shown).
In whole blood samples, calcein-AM-labeled platelets were undetectable after stimulation. The platelet aggregation in platelet-rich plasma samples was comparable to that in mixes with isolated platelets. The median differences in platelet aggregation percentage between platelet mix and platelet-rich plasma were À 4.8% (full range, À 8.5% to 2.0%) for TRAP, 0.8% (full range, À 3.4% to 0.8%) for ADP, and 11.0% (full range, 8.0-11.6%) for collagen-related peptide.
Characteristics of patients with AML or MDS and healthy individuals
Nineteen blood donors and 20 patients with AML (n = 18) or MDS (n = 2) were included. Among the patients with AML, 12 were newly diagnosed and eight had relapsed disease. None had acute promyelocytic leukemia. The median platelet count was 24 9 10 9 L -1
(IQR 14-32) for patients versus 243 9 10 9 L -1 (IQR 206-337) for healthy individuals. There was no difference in mean platelet volume: 11.1 AE 1.1 fL for patients versus 10.8 AE 1.1 fL for healthy individuals (P = 0.58). 
Flow-cytometric platelet aggregation in patients with AML and MDS
Patients with AML or MDS, overall, showed reduced platelet aggregation in comparison with healthy individuals (Fig. 5A) . Spontaneous platelet aggregation in unstimulated samples was low (≤ 4%) in the two groups. The average aggregate size after stimulation with collagen-related peptide was higher for patients than for healthy individuals (mean FSC 
Flow-cytometric platelet aggregation was associated with bleeding history
Six patients (all with AML) had a history of bleeding within the month prior to inclusion: three had epistaxis (recurrent and lasting for > 10 min or requiring medical attention), one had abnormal vaginal bleeding (lasting for > 7 days), one had overt gastrointestinal bleeding, and one had a large hematoma requiring medical attention. Overall, flow-cytometric platelet aggregation was lower in patients with a bleeding tendency than in those without (Fig. 5A) , and in fact, the results were able to identify all patients without a bleeding tendency (Fig. 5B) . Platelet aggregate size was not related to bleeding tendency (data not shown).
Platelet reactivity and surface receptor expression
With regard to unstimulated samples, the median percentage of P-selectin-positive platelets was significantly higher in patients than in healthy individuals (Table 1) . Upon platelet stimulation, platelets became activated in all samples. That is, the percentages of activated GPIIb-IIIa, CD63 and P-selectin increased relative to unstimulated samples (all P < 0.05). However, the median percentages of platelets positive for activated GPIIb-IIIa, CD63 and P-selectin after stimulation were significantly lower in patients. Also, MFI values after platelet stimulation were lower in patients than in healthy individuals, except for CD63 and P-selectin expression in ADP-activated samples (Table S1 ). There was no difference in platelet activation in terms of percentage of platelets positive for the marker (Fig. 6) or MFI values between patients with and without a bleeding tendency (Table S2 ) (P > 0.05 for all). The expression of GPIX (CD42a) was higher in patients than in healthy individuals, whereas no differences were observed for the other platelet surface receptors. For patients, there was a correlation between platelet aggregation and platelet reactivity when using the same agonist in both assays (Fig. 6 ).
Discussion
We established a flow-cytometric assay for evaluating in vitro platelet aggregation in patients with thrombocytopenia. The assay demonstrated that patients with AML or MDS had decreased platelet aggregation, and platelet aggregation results identified patients with a bleeding tendency. The use of flow cytometry for measuring platelet aggregation has been proposed previously [6, 15] . The flowcytometric assay presented here is optimized for testing in patients with thrombocytopenia. In contrast to most other available platelet aggregation methods [4] , this assay shows a low CV% (≤ 3%) with repeated measurements of stimulated platelet mixes, and low interindividual variation among healthy individuals.
For the final protocol, we mixed platelets with CAMUlabeled platelets in excess. This increased the likelihood that CV450-labeled platelets would aggregate primarily with CAMU-labeled platelets and create double-positive events. The 1 : 10 (platelet count/platelet count) ratio used yielded the highest platelet aggregation percentages. As results were affected by the platelet count ratio, it needed to remain constant to ensure comparability of samples. By chance, a fraction of CV450-labeled platelets will, expectedly, aggregate with platelets of the same dye. The fact that the highest platelet aggregation that we observed was 78% indicates the level of (undetectable) CV450 single-positive platelet aggregates. In agreement, CV450 single-positive platelets were activated by platelet stimulation as judged by P-selectin expression. Platelet aggregation was reduced for platelet counts of < 10-15 9 10 9 L -1 in the final platelet mix. This finding corresponds to the clinical observation that the risk of spontaneous, clinically significant bleeding increases considerably at platelet counts of ≤ 10 9 10 9 L -1 [3, 16] .
Thus, the effect of platelet transfusions might partly be the increased platelet count facilitating platelet aggregate formation by optimizing rheologic properties independently of the function of transfused platelets. This also points to the limitations in the use of whole blood or platelet-rich plasma in the flow-cytometric assay when samples from severely thrombocytopenic patients are tested, as platelet counts cannot be increased by concentration. Apart from this, the assay worked with platelet-rich plasma from donors, and yielded results comparable to those obtained with isolated platelets. The use of plateletrich plasma is a simpler approach, and is feasible for patients with mildly reduced platelet counts. It could be clinically useful, as most platelet aggregation methods are not valid in thrombocytopenic samples [4] . Other assay modifications could be of interest; a patient platelet mix combined with donor plasma could be compared with a platelet mix with autologous plasma, thereby enabling evaluation of the hemostatic properties of a patient's plasma. In previously published studies, platelet mixes were based on a combination of patient and donor platelets [6, 17] . We found this approach to yield higher platelet aggregation percentages than approaches using patient platelets only. Our concern is therefore that mild platelet function defects could be missed by this patient-donor platelet mix approach. On the other hand, it resembles the possible mechanism of transfusing donor platelets to a patient, and might be an appropriate ex vivo model for measuring the effects of platelet transfusion.
The in vitro effects of platelet inhibitors and the doseresponse curves of the flow-cytometric assay were similar to what have been observed with LTA. Thus, ticagrelor inhibited ADP-induced platelet aggregation and, to a lesser extent, TRAP-induced platelet aggregation. This effect could be mediated through the P 2 Y 12 receptor [18, 19] . Vorapaxar selectively inhibited TRAP-induced platelet aggregation [20] , and abciximab significantly reduced platelet aggregation induced by all agonists. However, at low concentrations (< 0.3 mg L À1 ), abciximab seemed to paradoxically activate ADP-induced platelet aggregation. This finding might be attributable to an intrinsic property of abciximab in activating GPIIb-IIIa and causing fibrinogen binding. Low concentrations of abciximab results in platelet aggregation because of access to ligand-induced binding sites on the receptor [21, 22] . This result emphasizes the high sensitivity of the present assay. Collagenrelated peptide-induced platelet aggregation was not fully inhibited by abciximab. It has been shown that some agonists recruit unblocked internal GPIIb-IIIa receptors and thereby induce platelet aggregation despite the presence of an inhibitor [23, 24] . The two patients with inherited platelet disorder (Wiscott-Aldrich syndrome or MYH-9-related thrombocytopenia) and thrombocytopenia were shown to have normal platelet aggregation. This is in agreement with neither of them having a bleeding tendency, and further supports the application of the flowcytometric platelet aggregation assay in patients with thrombocytopenia.
Patients with AML or MDS had reduced platelet aggregation and lower platelet activation after stimulation. The cause is probably multifactorial, and is not explained by reduced expression of platelet surface receptors. Previous studies have investigated the association between platelet [8, 9] or immune thrombocytopenia (ITP) [9, 25] . Leinoe et al. found lower platelet activation in AML patients than in healthy individuals [8] . AML patients with bleeding on the same day had lower P-selectin, CD63 and GPIb expression, but only P-selectin expression predicted new bleeds within 28 days [8] . Psaila et al. found higher expression of GPIIb-IIIa and P-selectin on stimulated platelets in AML/MDS patients with bleeding than in those with no bleeding [9] . In patients with ITP, high P-selectin and high GPIIb-IIIa expression in stimulated samples were associated with a low bleeding score [9, 25] . Although the results are conflicting, current evidence is in favor of the hypothesis that impaired platelet function is associated with bleeding in patients with thrombocytopenia. In addition, we showed that reduced platelet aggregation was associated with a bleeding tendency, whereas, in our study, platelet activation markers were not. Thus, flow-cytometric platelet aggregation could be a stronger indicator of bleeding risk than platelet activation markers. In agreement with this, our study shows that, for some agonists, a large change in platelet aggregation was associated with only a small change in the expression of platelet activation markers in stimulated samples. Platelet aggregation depends on multiple factors, including platelet activation, membrane composition, and granule contents. Therefore, it is plausible that a direct measurement of platelet aggregation reflects platelets' hemostatic capacity. Furthermore, platelet aggregation was superior to the platelet count for identifying a positive bleeding history, and was particularly useful for ruling out a bleeding tendency with 100% certainty. It must be noted, however, that we had only retrospective data on bleeding, and the ability of flow-cytometric platelet aggregation to predict bleeding must be confirmed in a prospective study.
Some other limitations exist. Higher agonist concentrations were needed for maximum platelet aggregation than are required for LTA. However, the required agonist concentration was equally high for isolated platelets and platelet-rich plasma, and was thus not related to the handling during platelet isolation procedure. Furthermore, the labeling itself did not affect platelet aggregation as tested with LTA. Thus, the high agonist concentration required in this assay might be related to the way in which aggregates are detected. The platelet aggregates detected in the flow-cytometric assay might be too small to change absorbance readings in LTA, and would therefore remain undetected by LTA. The results from this platelet aggregation assay might not be representative of platelet function in whole blood, as large platelets are removed during centrifugation [26] . Also, the results are based on a fraction of platelets in the mix. Finally, donors were allowed to take over-the-counter medicine for up to 24 h before sampling. For some donors, this may have reduced platelet aggregation. If so, the presented differences between platelet aggregation in AML patients and donors are conservative estimates.
The flow-cytometric platelet aggregation assay has several potential applications. It might be used for bleeding risk stratification and evaluation of the efficacy of platelet transfusion. Furthermore, it provides the possibility of identifying patients who are eligible for antiplatelet therapy despite being thrombocytopenic, and evaluating the efficacy of antiplatelet therapy. This research area is lacking evidence, because thrombocytopenic patients have generally been excluded from studies on antiplatelet treatment [27, 28] . Finally, the assay could facilitate the diagnostic work-up of inherited platelet disorders.
In conclusion, we established a flow-cytometric platelet aggregation assay, and found that patients with AML and MDS had reduced platelet aggregation and that low platelet aggregation identified a bleeding tendency. Addendum P. J. Vinholt, C. Nielsen, H. Frederiksen, A. M. Hvas, and U. Sprogøe designed the study. P. J. Vinholt, C. Nielsen, and H. Frederiksen recruited patients and conducted the experiments. P. J. Vinholt and C. Nielsen performed data management. All authors contributed to data interpretation, critical writing, and final approval of the manuscript.
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